摘要
目的 :观察奥氮平治疗精神分裂症阳性症状的疗效及安全性。方法 :采用随机临床对比研究。奥氮平组 31例 (男性 14例 ,女性 17例 ) ,剂量范围 5～ 2 0mg·d- 1;氯丙嗪组 2 7例 (男性 14例 ,女性 13例 ) ,剂量范围为 2 5～ 6 0 0mg·d- 1。结果 :奥氮平组治疗精神分裂症的显效率为 6 1% ,有效率为80 % ;而氯丙嗪组的显效率为 33% ,有效率为 5 2 % ,奥氮平组的临床疗效显著优于氯丙嗪组 (P <0 .0 5 )。奥氮平组的不良反应较少 ,未发现锥体外系不良反应及直立性低血压。结论 :奥氮平是一有效而安全的非典型性抗精神病药物 。
AIM: To observe the efficacy and safety of olanzapine in the treatment of the positive symptoms of schizophrenia. METHODS: A randomized controlled clinical study was used to compare the efficacy and safety of olanzapine and chlorpromazine. Fifty eight patients with schizophrenia were divided into two groups. Thirty one patients (M 14, F 17) were treated with olanzapine in a regimen of 5-20 mg·d -1 . Twenty seven patients (M 14, F 13) were treated with chlorpromazine in a regimen of 25-600 mg·d -1 . RESULTS: The excellent response rate and effective rate in olanzapine group were 61% and 80%;whereas those in chlorpromazine group were 33% and 52%. The results showed that the clinical effect of olanzapine was better than that of chlorpromazine( P < 0.05). CONCLUSION: Olanzapine is one of the novel safe atypical antipsychotics and is effective against the positive symptoms of schizophrenia with significantly fewer adverse reactions.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2003年第6期357-359,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
奥氮平
氯丙嗪
精神分裂症
阳性症状
临床疗效
chlorpromazine
antipsychotic agents
schizophrenia
drug therapy
randomized controlled trials
olanzapine
